A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Crizotinib
Related studies linked through entity extraction aliases.
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- Status
- RECRUITING
- Phase
- PHASE2
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Status
- COMPLETED
- Phase
- N/A
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
- Status
- UNKNOWN
- Phase
- PHASE3
Crizotinib Continuation Clinical Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Bioequivalence Study for Crizotinib Encapsulated Microsphere Formulation (eMS)
- Status
- COMPLETED
- Phase
- PHASE1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- Status
- RECRUITING
- Phase
- PHASE1
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
- Status
- COMPLETED
- Phase
- N/A
Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC
- Status
- RECRUITING
- Phase
- PHASE2